Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol 2019; 30: 863-70]. Ann Oncol 2018; 29(Suppl 4): iv192-237. doi: 10.1093/annonc/mdy275PlanchardDPopatSKerrKNovelloSSmitEFFaivre-FinnCet alMetastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis20193086370Ann Oncol 2018; 29(Suppl 4): iv192-23710.1093/annonc/mdy27530285222Open DOISearch in Google Scholar
World Health Organization. International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Cancer today. Lung. [internet]. [cited 2021 Feb 16]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdfWorld Health OrganizationAvailable athttps://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdfSearch in Google Scholar
Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, et al. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med 2015; 3: 1. doi: 10.1186/s40247-015-0013-zCarcerenyEMoránTCapdevilaLCrosSVilàLde LosLlanos Gil Met alThe epidermal growth factor receptor (EGRF) in lung cancer20153110.1186/s40247-015-0013-z436643225810955Open DOISearch in Google Scholar
Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 2019; 137: 113-22. doi: 10.1016/j.lungcan.2019.09.017GelattiACZDrilonASantiniFCOptimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)20191371132210.1016/j.lungcan.2019.09.017747884931568888Open DOISearch in Google Scholar
Vansteenkiste J, Wauters E. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years. Ann Oncol 2018; 29(Suppl 1): i1-i2. doi: 10.1093/annonc/mdx724VansteenkisteJWautersETyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years201829Suppl 1i1i210.1093/annonc/mdx72429462258Open DOISearch in Google Scholar
Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018; 29(Suppl 1): i10-i19. doi: 10.1093/annonc/mdx703WestoverDZugazagoitiaJChoBCLovlyCMPaz-AresLMechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors201829Suppl 1i10i1910.1093/annonc/mdx703645454729462254Open DOISearch in Google Scholar
Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, et al. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers 2019; 11: 923. doi: 10.3390/cancers11070923Santoni-RugiuEMelchiorLCUrbanskaEMJakobsenJNStrickerKGrauslundMet alIntrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance20191192310.3390/cancers11070923667866931266248Open DOISearch in Google Scholar
Mok TS, Wu Y-L, Ahn M-J, Kim HR, Ramalingam SS, Shepherd FA, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629-40. doi: 10.1056/NEJMoa1612674MokTSWuY-LAhnM-JKimHRRamalingamSSShepherdFAet alOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer20173766294010.1056/NEJMoa1612674676202727959700Open DOISearch in Google Scholar
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-25. doi: 10.1056/NEJMoa1713137SoriaJCOheYVansteenkisteJReungwetwattanaTChewaskulyongBLeeKHet alOsimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer20183781132510.1056/NEJMoa171313729151359Open DOISearch in Google Scholar
Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, et al. Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis. Oncologist 2020; 25: e598-601. doi: 10.1634/theoncologist.2019-0523CuferTCiuleanuTEBerzinecPGalffyGJakopovicMJassemJet alAccess to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis202025e59860110.1634/theoncologist.2019-0523706671732162818Open DOISearch in Google Scholar
Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 2018; 18: 269. doi: 10.1186/s12885-018-4023-4RyskaABerzinecPBrcicLCuferTDziadziuszkoRGottfriedMet alNSCLC molecular testing in Central and Eastern European countries20181826910.1186/s12885-018-4023-4584518429523116Open DOISearch in Google Scholar
Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. doi: 10.1515/raon-2017-0008ZadnikVPrimicZakelj MLokarKJarmKIvanusUZagarTCancer burden in Slovenia with the time trends analysis201751475510.1515/raon-2017-0008533017428265232Open DOISearch in Google Scholar
Zwitter M, Čufer T, Vrankar M, Kern I, Štupnik T, Rozman A, et al. Lung cancer in Slovenia. J Thorac Oncol 2019; 14: 1327-31. doi: 10.1016/j. jtho.2019.02.025ZwitterMČuferTVrankarMKernIŠtupnikTRozmanAet alLung cancer in Slovenia20191413273110.1016/j.jtho.2019.02.02531345331Open DOISearch in Google Scholar
Zanetti R, Sacchetto L, Coebergh JW, Rosso S. To accelerate cancer prevention in Europe: challenges for cancer registries. Eur J Cancer 2018; 104: 151-9. doi: 10.1016/j.ejca.2018.09.001ZanettiRSacchettoLCoeberghJWRossoSTo accelerate cancer prevention in Europe: challenges for cancer registries2018104151910.1016/j.ejca.2018.09.00130352383Open DOISearch in Google Scholar
Thunissen E, Weynand B, Udovicic-Gagula D, Brcic L, Szolkowska M, Hofman P, et al. Lung cancer biomarker testing: perspective from Europe. Transl Lung Cancer Res 2020; 9: 887-897. doi: 10.21037/tlcr.2020.04.07ThunissenEWeynandBUdovicic-GagulaDBrcicLSzolkowskaMHofmanPet alLung cancer biomarker testing: perspective from Europe2020988789710.21037/tlcr.2020.04.07735411932676354Open DOISearch in Google Scholar
Janzic U, Knez L, Janzic A, Cufer T. Time to access to novel anticancer drugs and the correlation with ESMO-magnitude of clinical benefit scale in Slovenia. Expert Rev Pharmacoecon Outcomes Res 2019; 19: 717-23. doi: 10.1080/14737167.2019.1702879JanzicUKnezLJanzicACuferTTime to access to novel anticancer drugs and the correlation with ESMO-magnitude of clinical benefit scale in Slovenia2019197172310.1080/14737167.2019.170287931826655Open DOISearch in Google Scholar
Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness. Am J Health Syst Pharm 2020; 77: 1466-76. doi: 10.1093/ ajhp/zxaa197HirshVSinghJOptimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness20207714667610.1093/ajhp/zxaa197747221032885829Open DOISearch in Google Scholar
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 2017; 28: 2715-24. doi: 10.1093/ annonc/mdx404LeducCMerlioJPBesseBBlonsHDebieuvreDBringuierPPet alClinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program20172827152410.1093/annonc/mdx40428945865Open DOISearch in Google Scholar
Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological characteristics, EGFR status and management patterns of advanced non-small cell lung cancer patients: the Greek REASON observational registry study. Anticancer Res 2018; 38: 3735-44. doi: 10.21873/anticanres.12654SyrigosKNGeorgouliasVZarogoulidisKMakrantonakisPCharpidouAChristodoulouCEpidemiological characteristics, EGFR status and management patterns of advanced non-small cell lung cancer patients: the Greek REASON observational registry study20183837354410.21873/anticanres.1265429848736Open DOISearch in Google Scholar
Schuette W, Schirmacher P, Eberhardt WEE, Dietel M, Zirrgiebel U, Muehlenhoff L, et al. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer 2018; 18: 135. doi: 10.1186/s12885-018-4032-3SchuetteWSchirmacherPEberhardtWEEDietelMZirrgiebelUMuehlenhoffLet alTreatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study20181813510.1186/s12885-018-4032-3579990429402243Open DOISearch in Google Scholar
Reale ML, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D, et al. Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer 2020; 140: 71-9. doi: 10.1016/j. lungcan.2019.12.006RealeMLChiariRTiseoMVitielloFBarbieriFCortinovisDet alBe-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients202014071910.1016/j.lungcan.2019.12.00631884129Open DOISearch in Google Scholar
Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open 2020; 5: e001011. doi: 10.1136/ esmoopen-2020-001011PluzanskiAKrzakowskiMKowalskiDDziadziuszkoRReal-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients20205e00101110.1136/esmoopen-2020-001011764061933148621Open DOISearch in Google Scholar
Pereira I, Gaspar C, Pina M, Azevedo I, Rodrigues A. Real-world T790M mutation frequency and impact of rebiopsy in patients with EGFR-mutated advanced non-small cell lung cancer. Cureus 2020; 12: e12128. doi: 10.7759/ cureus.12128PereiraIGasparCPinaMAzevedoIRodriguesAReal-world T790M mutation frequency and impact of rebiopsy in patients with EGFR-mutated advanced non-small cell lung cancer202012e1212810.7759/cureus.12128781017533489541Open DOISearch in Google Scholar
Gijtenbeek RGP, Damhuis RAM, Groen HJM, van der Wekken AJ, van Geffen WH. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. Clin Lung Cancer 2020; 21: e647-53. doi: 10.1016/j. cllc.2020.05.019GijtenbeekRGPDamhuisRAMGroenHJMvander Wekken AJvanGeffen WHNationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer202021e6475310.1016/j.cllc.2020.05.01932636159Open DOISearch in Google Scholar
Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberté F, Duh MS, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 2020; 20: 356. doi: 10.1186/s12885-020-06826-0ChiangACFernandesAWPavilackMWuJWLalibertéFDuhMSet alEGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors20202035610.1186/s12885-020-06826-0718968832345265Open DOISearch in Google Scholar
Cuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, et al. Real-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients in Belgium: results from the REVEAL study. Drugs Real World Outcomes 2021; 8: 141-52. doi: 10.1007/s40801-021-00243-wCuppensKLodewyckxLDemedtsIDecosterLColinetBDeschepperKet alReal-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients in Belgium: results from the REVEAL study202181415210.1007/s40801-021-00243-w812895333710523Open DOISearch in Google Scholar
Addeo A, Hochmair M, Janzic U, Dudnik E, Charpidou A, Płużański A, et al. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Ther Adv Med Oncol 2021; 13: 1-11. doi: 10.1177/17588359211059874AddeoAHochmairMJanzicUDudnikECharpidouAPłużańskiAet alTreatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)20211311110.1177/17588359211059874884214935173817Open DOISearch in Google Scholar
Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, et al. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2017; 2: e000214. doi: 10.1136/esmoopen-2017-000214GotoYTanaiCYohKHosomiYSakaiHKatoTet alContinuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study20172e00021410.1136/esmoopen-2017-000214560471529018574Open DOISearch in Google Scholar
Unk M, Mohorčič K, Osrajnik I, Čufer T. Lung cancer – Slovenian clinical practice guidelines in systemic treatment 2017. [Slovenian]. Onkologija 2017; 21: 52-62.UnkMMohorčičKOsrajnikIČuferTLung cancer – Slovenian clinical practice guidelines in systemic treatment 20172017215262Search in Google Scholar
Minari R, Mazzaschi G, Bordi P, Gnetti L, Alberti G, Altimari A, et al. Detection of EGFR-activating and T790M mutations using liquid biopsy in patients with EGFR-mutated non-small-cell lung cancer whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors: a multicenter real-life retrospective study. Clin Lung Cancer 2020; 21: e464-73. doi: 10.1016/j.cllc.2020.02.021MinariRMazzaschiGBordiPGnettiLAlbertiGAltimariAet alDetection of EGFR-activating and T790M mutations using liquid biopsy in patients with EGFR-mutated non-small-cell lung cancer whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors: a multicenter real-life retrospective study202021e4647310.1016/j.cllc.2020.02.02132276870Open DOISearch in Google Scholar
Dal Maso A, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, et al. Clinical features and progression pattern of acquired T790M-positive compared with T790M-negative EGFR mutant non-small-cell lung cancer: catching tumor and clinical heterogeneity over time through liquid biopsy. Clin Lung Cancer 2020; 21: 1-14.e3. doi: 10.1016/j.cllc.2019.07.009DalMaso ALorenziMRocaEPilottoSMacerelliMPoloVet alClinical features and progression pattern of acquired T790M-positive compared with T790M-negative EGFR mutant non-small-cell lung cancer: catching tumor and clinical heterogeneity over time through liquid biopsy202021114e310.1016/j.cllc.2019.07.00931601525Open DOISearch in Google Scholar
Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Front Oncol 2014; 4: 248. doi: 10.3389/fonc.2014.00248OwenSSouhamiLThe management of brain metastases in non-small cell lung cancer2014424810.3389/fonc.2014.00248416409625309873Open DOISearch in Google Scholar
Page S, Milner-Watts C, Perna M, Janzic U, Vidal N, Kaudeer N, et al. Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer 2020; 132: 187-98. doi: 10.1016/j.ejca.2020.03.006PageSMilner-WattsCPernaMJanzicUVidalNKaudeerNet alSystemic treatment of brain metastases in non-small cell lung cancer20201321879810.1016/j.ejca.2020.03.00632380429Open DOISearch in Google Scholar
Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 2017; 9: 2510-20. doi: 10.21037/ jtd.2017.07.57LiLLuoSLinHYangHChenHLiaoZet alCorrelation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer2017925102010.21037/jtd.2017.07.57559420128932557Open DOISearch in Google Scholar
Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014; 48: 173-83. doi: 10.2478/raon-2014-0016StanicKZwitterMHitijNTKernISadikovACuferTBrain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival2014481738310.2478/raon-2014-0016407803624991207Open DOISearch in Google Scholar
Shinde A, Akhavan D, Sedrak M, Glaser S, Amini A. Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases. CNS Oncol 2019; 8: CNS27. doi: 10.2217/cns-2018-0016ShindeAAkhavanDSedrakMGlaserSAminiAShifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases20198CNS2710.2217/cns-2018-0016649901530701987Open DOISearch in Google Scholar
Roeper J, Kurz S, Grohé C, Griesinger F. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncol 2021; 17: 471-86. doi: 10.2217/fon-2020-0854RoeperJKurzSGrohéCGriesingerFOptimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC2021174718610.2217/fon-2020-085433094641Open DOISearch in Google Scholar
Nadler E, Pavilack M, Espirito JL, Clark J, Fernandes A. Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors. Adv Ther 2020; 37: 946-54. doi: 10.1007/ s12325-020-01221-4NadlerEPavilackMEspiritoJLClarkJFernandesAObservational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors2020379465410.1007/s12325-020-01221-431955357Open DOISearch in Google Scholar
Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small cell lung cancer. Transl Cancer Res 2020; 9: 2982-91. doi: 10.21037/ tcr.2020.03.10WangFLiCWuQLuHEGFR exon 20 insertion mutations in non-small cell lung cancer2020929829110.21037/tcr.2020.03.10879901235117654Open DOISearch in Google Scholar
Remon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev 2020; 90: 102105. doi: 10.1016/j.ctrv.2020.102105RemonJHendriksLELCardonaAFBesseBEGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins20209010210510.1016/j.ctrv.2020.10210532979839Open DOISearch in Google Scholar
Dent RAG, Cole P. In vitro maturation of monocytes in squamous carcinoma of the lung. Br J Cancer 1981; 43: 486-95. doi: 10.1038/bjc.1981.71DentRAGColePIn vitro maturation of monocytes in squamous carcinoma of the lung1981434869510.1038/bjc.1981.7120106367236490Open DOISearch in Google Scholar
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919. doi: 10.1136/bmj.i4919SterneJAHernanMAReevesBCSavovicJBerkmanNDViswanathanMet alROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions2016355i491910.1136/bmj.i4919506205427733354Open DOISearch in Google Scholar
Chapman S, Nakielny R. A guide to radiological procedures. London: Bailliere Tindall; 1986.ChapmanSNakielnyRLondonBailliere Tindall1986Search in Google Scholar
Evans R, Alexander P. Mechanisms of extracellular killing of nucleated mammalian cells by macrophages. In: Nelson DS, editor. Immunobiology of macrophage. New York: Academic Press; 1976. p. 45-74.EvansRAlexanderPMechanisms of extracellular killing of nucleated mammalian cells by macrophagesInNelsonDSeditorNew YorkAcademic Press;1976p45–7410.1016/B978-0-12-514550-3.50027-XSearch in Google Scholar